Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SRT 2183 是一种选择性Sirtuin-1激活剂,其EC1.5值为 0.36 μM。它诱导生长停滞和凋亡,同时伴随 STAT3 和 NF-κB 去乙酰化,并降低 c-Myc 蛋白水平。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 428 | 现货 | ||
2 mg | ¥ 617 | 现货 | ||
5 mg | ¥ 987 | 现货 | ||
10 mg | ¥ 1,480 | 现货 | ||
25 mg | ¥ 2,530 | 现货 | ||
50 mg | ¥ 3,720 | 现货 | ||
100 mg | ¥ 5,290 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,090 | 现货 |
产品描述 | SRT 2183 is a selective activator of Sirtuin-1 (SIRT1, EC1.5 : 0.36 μM). |
靶点活性 | SIRT1:0.36 μM (EC1.5) |
体外活性 | SRT2183 leads to increased mRNA levels of pro-apoptosis and DNA-damage-response genes, accompanied by accumulation of phospho-H2A.X levels.?Combination of SRT2183 with panobinostat enhanced the anti-growth and anti-survival effects mediated by either compound alone.?Quantitative-PCR confirmed that the panobinostat in combination with SRT2183, SRT501 or resveratrol leads to greater upregulation of GADD45G than any of the single agents.?Panobinostat plus SRT2183 in combination showed greater inhibition of c-Myc protein levels and phosphorylation of H2A.X, and increased acetylation of p53.?Furthermore, EMSA revealed that NF-κB binds directly to the GADD45G promoter, while STAT3 binds indirectly in complexes with NF-κB.?In addition, the binding of NF-κB/STAT3 complexes to the GADD45G promoter is inhibited following panobinostat, SRT501 or resveratrol treatment.?Moreover, the combination of panobinostat with SRT2183, SRT501 or resveratrol induces a greater binding repression than either agent alone[1]. |
分子量 | 468.57 |
分子式 | C27H24N4O2S |
CAS No. | 1001908-89-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 240 mg/mL (512.2 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1342 mL | 10.6708 mL | 21.3415 mL | 53.3538 mL |
5 mM | 0.4268 mL | 2.1342 mL | 4.2683 mL | 10.6708 mL | |
10 mM | 0.2134 mL | 1.0671 mL | 2.1342 mL | 5.3354 mL | |
20 mM | 0.1067 mL | 0.5335 mL | 1.0671 mL | 2.6677 mL | |
50 mM | 0.0427 mL | 0.2134 mL | 0.4268 mL | 1.0671 mL | |
100 mM | 0.0213 mL | 0.1067 mL | 0.2134 mL | 0.5335 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SRT 2183 1001908-89-9 Apoptosis Chromatin/Epigenetic DNA Damage/DNA Repair Sirtuin Inhibitor SRT-2183 inhibit SRT2183 inhibitor